PBP Stock Overview
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast-moving consumer products in Australia and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for PBP from our risk checks.
My Notes
NewNotes are coming soon
Probiotec Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$2.23 |
52 Week High | AU$2.42 |
52 Week Low | AU$2.02 |
Beta | 0.44 |
1 Month Change | 1.36% |
3 Month Change | 3.24% |
1 Year Change | 0.45% |
3 Year Change | -8.61% |
5 Year Change | 159.30% |
Change since IPO | 93.07% |
Recent News & Updates
Shareholder Returns
PBP | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | 2.3% | -3.6% | 0.8% |
1Y | 0.5% | -29.0% | 2.2% |
Return vs Industry: PBP exceeded the Australian Pharmaceuticals industry which returned -29% over the past year.
Return vs Market: PBP underperformed the Australian Market which returned 2.2% over the past year.
Price Volatility
PBP volatility | |
---|---|
PBP Average Weekly Movement | 3.9% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 8.5% |
10% most volatile stocks in AU Market | 15.5% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PBP is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PBP's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | n/a | Wes Stringer | https://www.probiotec.com.au |
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, ointments, and suspensions; powders and powder blending; and sprays, as well as manufactures and packages finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.
Probiotec Limited Fundamentals Summary
PBP fundamental statistics | |
---|---|
Market Cap | AU$181.35m |
Earnings (TTM) | AU$13.71m |
Revenue (TTM) | AU$182.33m |
13.2x
P/E Ratio1.0x
P/S RatioIs PBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PBP income statement (TTM) | |
---|---|
Revenue | AU$182.33m |
Cost of Revenue | AU$125.09m |
Gross Profit | AU$57.24m |
Other Expenses | AU$43.53m |
Earnings | AU$13.71m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0.17 |
Gross Margin | 31.39% |
Net Profit Margin | 7.52% |
Debt/Equity Ratio | 61.3% |
How did PBP perform over the long term?
See historical performance and comparison